[ad_1]
\n<\/p>\n
New data released today in\u00a0CDC\u2019s\u00a0MMWR\u00a0<\/a>show that\u00a0nirsevimab, a long-acting monoclonal antibody product,\u00a0was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).\u00a0RSV is the leading cause of hospitalization among infants in the United States, and this finding supports CDC\u2019s recommendation to protect\u00a0infants\u00a0in their first RSV season\u00a0by giving the infant\u00a0nirsevimab if the mother did not receive the maternal RSV vaccine during pregnancy.<\/p>\n The current RSV season is the first time nirsevimab was available to protect infants from severe RSV, so the data released today\u00a0are the first United States estimates\u00a0of\u00a0nirsevimab\u00a0effectiveness in\u00a0protecting\u00a0infants\u00a0against RSV-related hospitalization\u00a0in their first season of potential exposure to the virus.<\/p>\n The study looked at 699 infants from October 2023 through February 2024 using early data from CDC\u2019s New Vaccine Surveillance Network (NVSN)<\/a>, a population-based surveillance platform that monitors pediatric respiratory viruses to assess immunization effectiveness. Results show that nirsevimab was 90% effective at preventing RSV-associated hospitalization in infants during their first RSV season. These results reflect a shorter surveillance period due to the introduction of this new product in August 2023<\/a>. Nirsevimab effectiveness may be lower over a full RSV season (October through March in most of the United States). With increasing availability of nirsevimab in future RSV seasons, CDC\u00a0will assess its effectiveness over an entire season.<\/p>\n RSV prevention products remain our single most important tool to protect\u00a0infants from RSV. Healthcare providers should recommend\u00a0either:<\/p>\n \u00a0<\/p>\n CDC\u00a0continues to monitor\u00a0the safety and\u00a0effectiveness\u00a0of nirsevimab and maternal RSV vaccines.<\/p>\n<\/div>\n\n